Gastroenterology and Hepatology最新文献

Exploring Screening for Colorectal Cancer.

Gastroenterology and Hepatology Pub Date : 2025-03-01

Gary R Lichtenstein

引用次数: 0

Management of Uncomplicated Luminal Crohn's Disease.

Gastroenterology and Hepatology Pub Date : 2025-03-01

引用次数: 0

The Evolving Role of Weight Loss Pharmacotherapy.

Gastroenterology and Hepatology Pub Date : 2025-03-01

Shayan Amini, Daniel A Burkholder, Ronan P Allencherril, Raj Shah, Thomas R McCarty

{"title":"The Evolving Role of Weight Loss Pharmacotherapy.","authors":"Shayan Amini, Daniel A Burkholder, Ronan P Allencherril, Raj Shah, Thomas R McCarty","doi":"","DOIUrl":"","url":null,"abstract":"Obesity is a complex disease, afflicting millions of individuals worldwide. Multiple treatment options exist, including dietary and lifestyle modifications, pharmacotherapy, endobariatrics, and surgery. Although diet and exercise remain crucial to the long-term management of obesity, their effectiveness as monotherapy is limited. Adjunctive therapy, therefore, has become a tool associated with more durable weight loss results. This article serves to explore the expanding pharmacologic options available for the treatment of obesity. Traditional pharmacotherapy includes phentermine/topiramate and bupropion/naltrexone, both of which have been shown to aid in weight loss. More recent novel therapies include glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists, which have shown even more marked weight loss and improvement in obesity-associated comorbid conditions compared with alternative medications. Despite their effectiveness, barriers to widespread use include their cost, insurance approval, and side effect profile. Further studies are underway examining the role of pharmacotherapy in conjunction with endoscopic bariatric therapies as well as bariatric surgery.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 3","pages":"172-179"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Azathioprine or Mycophenolate Mofetil: Which Should Be Used in Patients With Autoimmune Hepatitis? 硫唑嘌呤还是霉酚酸酯？自身免疫性肝炎患者应该使用哪种疗法？

Gastroenterology and Hepatology Pub Date : 2025-03-01

Alan Bonder

引用次数: 0

Examining the Use of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

Gastroenterology and Hepatology Pub Date : 2025-03-01

Gary R Lichtenstein

引用次数: 0

Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

Gastroenterology and Hepatology Pub Date : 2025-03-01

Naim Alkhouri

引用次数: 0

Evolution of Therapy in Autoimmune Hepatitis.

Gastroenterology and Hepatology Pub Date : 2025-03-01

Ilkay Ergenc, Alexandra Frolkis, Yooyun Chung, Michael A Heneghan

{"title":"Evolution of Therapy in Autoimmune Hepatitis.","authors":"Ilkay Ergenc, Alexandra Frolkis, Yooyun Chung, Michael A Heneghan","doi":"","DOIUrl":"","url":null,"abstract":"Autoimmune hepatitis (AIH) is an immune-mediated liver disease characterized by a spectrum of clinical manifestations, ranging from asymptomatic liver enzyme abnormalities to fulminant liver failure. Despite significant achievements, the backbone of first-line AIH treatment, including corticosteroids and azathioprine, has remained nearly unchanged for 5 decades. However, up to 20% of patients experience insufficient response, loss of response, or treatment intolerance. For patients intolerant to first-line therapy, second-line options include mercaptopurine and mycophenolate mofetil (MMF), with recent debates regarding MMF's potential role in first-line treatment. A significant advancement has been the tailoring of azathioprine doses and manipulating blood levels with the addition of low-dose allopurinol by using therapeutic metabolite monitoring for patients with insufficient or lost biochemical response. Increasing experience with calcineurin inhibitors and biologic agents, particularly rituximab and infliximab, has demonstrated their efficacy as third-line options. Notably, B-cell activating factor blockade emerges as a promising future treatment. This article delves into the chronological evolution of AIH treatment, focusing on recent advances.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 3","pages":"152-160"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When to Consider Acupuncture for Disorders of Gut-Brain Interaction. 何时考虑针灸治疗肠脑互动障碍？

Gastroenterology and Hepatology Pub Date : 2025-03-01

Anthony J Lembo

引用次数: 0

Use of Interleukin-23 Inhibitors for the Treatment of Inflammatory Bowel Disease. 使用白细胞介素-23 抑制剂治疗炎症性肠病。

Gastroenterology and Hepatology Pub Date : 2025-03-01

Edouard Louis

引用次数: 0

Management of Complicated Crohn's Disease.

Gastroenterology and Hepatology Pub Date : 2025-03-01

引用次数: 0